CAR‐T cells in first relapse of paediatric Down syndrome B‐cell acute lymphoblastic leukaemia: Oncologist perspectives

Summary Management of B‐cell acute lymphoblastic leukaemia (B‐ALL) in patients with Down syndrome (DS‐ALL) is complicated by increased toxicity and relapse rates. For first relapse of DS‐ALL, optimal management is uncertain. Chimeric antigen receptor T‐cell (CAR‐T) therapy offers an alternate approach for remission induction and/or definitive curative therapy, and recent reports suggest similar efficacy and tolerability in DS and non‐DS patients. We distributed an international survey to paediatric oncologists treating DS‐ALL querying opinions on therapy, monitoring and toxicity in this population. Among 89 respondents, 76%, 80% and 64% favoured definitive CAR‐T therapy without intent for subsequent haematopoietic stem cell transplantation (HSCT) for early medullary relapse, early and late isolated extra‐medullary relapse respectively. For late medullary relapse, 47% preferred definitive CAR‐T whereas 51% chose definitive chemoimmunotherapy. Only a minority of respondents selected HSCT as a planned approach for any first relapse: 11%–15% for early relapse; 3%–5% for late relapse. The main perceived benefit of CAR‐T therapy was its favourable toxicity profile. Overall, 56% and 77% of respondents felt that it should be considered standard of care for low and high‐risk relapse of DS‐ALL respectively. Survey responses suggest that developing guidelines to integrate use of CAR‐T is warranted for first relapse in DS‐ALL.

Authors

Institutions

Publication Details

Journal
British Journal of Haematology
Published
2026-11-19
DOI
https://doi.org/10.1111/bjh.70945
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

CAR‐T cells in first relapse of paediatric Down syndrome B‐cell acute lymphoblastic leukaemia: Oncologist perspectives

Rishi Sury Kotecha, Karen R. Rabin, Anupam R. Verma, Susana Rives et al.
British Journal of Haematology
CAR-T cell therapy research
article

CAR‐T cells in first relapse of paediatric Down syndrome B‐cell acute lymphoblastic leukaemia: Oncologist perspectives

Rishi Sury Kotecha, Karen R. Rabin, Anupam R. Verma, Susana Rives, Nirali N. Shah, Deepa Bhojwani, Johann K. Hitzler, Jeremy D. Rubinstein, Joerg Krueger, Sara Ghorashian, Colleen Annesley, Sara Zarnegar
article en

Abstract

Summary Management of B‐cell acute lymphoblastic leukaemia (B‐ALL) in patients with Down syndrome (DS‐ALL) is complicated by increased toxicity and relapse rates. For first relapse of DS‐ALL, optimal management is uncertain. Chimeric antigen receptor T‐cell (CAR‐T) therapy offers an alternate approach for remission induction and/or definitive curative therapy, and recent reports suggest similar efficacy and tolerability in DS and non‐DS patients. We distributed an international survey to paediatric oncologists treating DS‐ALL querying opinions on therapy, monitoring and toxicity in this population. Among 89 respondents, 76%, 80% and 64% favoured definitive CAR‐T therapy without intent for subsequent haematopoietic stem cell transplantation (HSCT) for early medullary relapse, early and late isolated extra‐medullary relapse respectively. For late medullary relapse, 47% preferred definitive CAR‐T whereas 51% chose definitive chemoimmunotherapy. Only a minority of respondents selected HSCT as a planned approach for any first relapse: 11%–15% for early relapse; 3%–5% for late relapse. The main perceived benefit of CAR‐T therapy was its favourable toxicity profile. Overall, 56% and 77% of respondents felt that it should be considered standard of care for low and high‐risk relapse of DS‐ALL respectively. Survey responses suggest that developing guidelines to integrate use of CAR‐T is warranted for first relapse in DS‐ALL.

British Journal of Haematology
Northwestern University (US), University of Southern California (US), Cincinnati Children's Hospital Medical Center (US), Lurie Children's Hospital (US), Seattle Children's Hospital (US), National Institutes of Health (US), Hospital Sant Joan de Déu Barcelona (ES), Children's Hospital of Los Angeles (US), The Kids Research Institute Australia (AU), The University of Western Australia (AU), University of California, San Francisco (US), University of Toronto (CA), University of Washington (US), Curtin University (AU), Great Ormond Street Hospital (GB), Princess Margaret Hospital for Children (AU), Hospital for Sick Children (CA), University of California San Francisco Medical Center (US), Parc Sanitari Sant Joan de Déu (ES), National Cancer Institute (US), Center for Cancer Research (US), Rainbow Babies & Children's Hospital (US), Perth Children's Hospital (AU), Case Comprehensive Cancer Center (US), Case Western Reserve University (US), University of Cincinnati (US)
CAR-T cell therapy research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon